drugset / Trial / NCT00712114
Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential anti-inflammatory activity of an investigational agent, HE3286, when administered orally for 29 days to patients with rheumatoid arthritis that are taking a stable dose of methotrexate.
Timeline
- Start
- 2008-07
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bezisterim | Small molecule | 10 mg | Oral |
| Subject | bezisterim | Small molecule | 20 mg | Oral |
| Subject | bezisterim | Small molecule | 40 mg | Oral |